SAINT PAUL, Minn., Jan. 27, 2016 /PRNewswire/ -- MD Biosciences (http://www.mdbiosciences.com) today announced the addition of its suite of in vivo and in vitro cancer models to its family of preclinical contract research services. MD Biosciences' oncology research program specializes in murine solid tumors for subcutaneous and orthoptopic models (for example, advanced breast cancer and renal cancer) with a specific focus on the immune aspects of disease development and progression. The comprehensive services include both syngeneic and xenograft models with readouts for longitudinal tumor monitoring (for some models), longitudinal blood phenotyping (immune cell distribution, biomarkers, etc.), end time-point primary/metastatic tumor evaluation, tumor tissue-specific cellular analysis using intravascular staining (cells: epithelial, endothelial, immune etc.), biomarker analysis (blood, tumor tissue, spleen, lymph node etc.) and histological grading and evaluation of tumor specific tissue (H&E, IHC, etc.).
"Our onco-immunology research team is comprised of skilled scientists with deep-rooted expertise in a highly complex field," said Eddie Moradian, MD Biosciences CEO. "We at MD Biosciences are excited to bring our high level of expertise and our novel models to assist sponsors and partners in reaching their programs' developmental goals. This new suite of capabilities compliments our existing, best-in-class services in other disease areas."
About MD Biosciences:
MD Biosciences Preclinical Research Services is a leading provider of contract research in the core areas of inflammation, immunological, oncological, neurological and metabolic diseases. The suite of services includes a wide range of cell-based assays, in vivo disease models, translational models as well as models for the identification of the mode of action of novel drugs and compounds. The services are supported by GLP in vitro diagnostic laboratories for the testing of samples by using multiplexed genomic and proteomic methods. Proprietary models include pig models for neuropathic pain, wound healing and other key disease areas.
MD Biosciences Clinical and Diagnostics Division provides in vitro services for the testing of clinical samples. Methods include proprietary methylation assays as well as analysis of genetic markers for cancer biopsies. These methods are critical in providing personalized therapy to patients. MD Biosciences Clinical and Diagnostics Division provide analysis services for pharmaceutical clinical studies. Services include assay development, validation as well as sample acquisition, processing and reporting. All services are provided from the MD Biosciences GLP and CLIA accredited laboratories based in Saint Paul, MN.
MD Biosciences Bioproducts Division provides proprietary products for research in life sciences and specifically in drug discovery. Flagship products include highly purified collagen for the study of arthritis; ArthritoMab®, a widely used, proprietary cocktail of monoclonal antibodies for the induction of arthritis in murine studies; NeuroFreeze® kit for the preservation of harvested neuronal cells; and the newly released anti-IgD monoclonal antibody for the study of B-cell activation.
Eddie Moradian, PhD
651 641 2836
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/md-biosciences-announces-launch-of-its-onco-immunology-suite-of-preclinical-services-300209955.html
SOURCE MD Biosciences, Inc.